TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05933655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Coach
Description: Peer coaching session to support shared decision making among patient with limited health literacy.
Study: NCT06081361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: Oral, 400mg qd for 2 weeks, then 200 mg 3 times per week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bedaquiline
Description: Oral, 400mg qd for 2 weeks, then 200 mg 3 times per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid
Description: Oral, 100mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contezolid
Description: Oral, 800mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Oral, 400mg qd for weight \<50kg, 600-750mg qd for weight ≥50kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: Oral, 400mg qd for weight \<50kg, 600-750mg qd for weight ≥50kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Oral, 400mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Oral, 400mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine
Description: Oral, 100mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clofazimine
Description: Oral, 100mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: Oral, 600mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cycloserine
Description: Oral, 250mg bid
Study: NCT04513132

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-dTMS
Description: The sham-dTMS has the same appearance with the real stimulation coil, which can not generate magnetic field. A sound generator is built in the coil beat to simulate the sound of the real stimulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-dTMS
Description: The sham-dTMS has the same appearance with the real stimulation coil, which can not generate magnetic field. A sound generator is built in the coil beat to simulate the sound of the real stimulation.
Study: NCT05164835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmaceutical follow-up
Description: Pharmaceutical follow-up over 1 year and pharmaceutical interviews during the various medical consultation appointments.~In addition to the usual care:~* Delivery of questionnaire at the time defined in the protocol. The questionnaires will be given during the waiting time of the patients at the University Hospital of Limoges.~* Extension of the duration of the usual interview by 10 minutes in order to collect the desired information.
Study: NCT05771935

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound guided radial versus ulnar artery cannulation
Description: Ultrasound examination will be performed using a hockey stick, high frequency (5-10 MHz) ultrasound probe (S-NerveTM; SonoSite Inc., Bothell, WA, USA).~. Arterial cannulation will be performed using the long axis view (in-plane) technique with a 24 or 22-gauge canulae according to the operator preference. Cannulation will be considered complete when the arterial waveform is confirmed on the monitor. If cannulation is unsuccessful within the third attempt or within 10 min, the case will be considered a failure at the chosen artery. After the failure, an alternative site will be used for cannulation and the case will be excluded from the study.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided radial versus ulnar artery cannulation
Description: Ultrasound examination will be performed using a hockey stick, high frequency (5-10 MHz) ultrasound probe (S-NerveTM; SonoSite Inc., Bothell, WA, USA).~. Arterial cannulation will be performed using the long axis view (in-plane) technique with a 24 or 22-gauge canulae according to the operator preference. Cannulation will be considered complete when the arterial waveform is confirmed on the monitor. If cannulation is unsuccessful within the third attempt or within 10 min, the case will be considered a failure at the chosen artery. After the failure, an alternative site will be used for cannulation and the case will be excluded from the study.
Study: NCT05491538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Cognition and Interaction Training-Work Edition (SCIT-WE)
Description: Participants will attend 1 2-hour skills training group weekly for 13 weeks after enrolling in supported employment. In addition to the group session, participants have a 15-30 minute individual session with the group facilitator weekly to review homework and complete a 10-15 minute exercise with their employment specialist each week to practice skills outside of group. The 13-week skills group is followed by 10 skills review/application sessions conducted during 10 supported employment sessions in the next 13 weeks.
Study: NCT05348473

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alpha type
Description: Tips of the seton will be tied as alpha-shaped.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Beta type
Description: Tips of the seton in this group will be overlapped and tied

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comfort type
Description: Knotless seton will be applied
Study: NCT06615739

Intervention type: DEVICE
Intervention: Regenerex Tissue Attachment Augments
Description: Patient will have been previously implanted with Regenerex Tissue Attachment Augments in combination with the Comprehensive Segmental Revision System
Study: NCT06681584

Intervention type: DIAGNOSTIC_TEST
Intervention: CTCA
Description: CTCA is a non-invasive test for diagnosis of anatomic coronary stenosis. Additionally, the diagnostic performance of FFRB (derived from in house calculation) with CCTA data in patients with intermediate coronary artery disease (CAD), as compared to an invasive FFR reference standard (FFR\<=0.80)

Intervention type: DIAGNOSTIC_TEST
Intervention: CTCA
Description: CTCA is a non-invasive test for diagnosis of anatomic coronary stenosis. Additionally, the diagnostic performance of FFRB (derived from in house calculation) with CCTA data in patients with intermediate coronary artery disease (CAD), as compared to an invasive FFR reference standard (FFR\<=0.80)
Study: NCT06681779

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation
Description: Transcutaneous electrical stimulation will be used to create noxious stimuli for the GCS exam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation
Description: Transcutaneous electrical stimulation will be used to create noxious stimuli for the GCS exam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation
Description: Transcutaneous electrical stimulation will be used to create noxious stimuli for the GCS exam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation
Description: Transcutaneous electrical stimulation will be used to create noxious stimuli for the GCS exam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation
Description: Transcutaneous electrical stimulation will be used to create noxious stimuli for the GCS exam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation
Description: Transcutaneous electrical stimulation will be used to create noxious stimuli for the GCS exam
Study: NCT03686657

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 1000 mg metformin-HCL XR once-a-day or maintenance dose of metformin for 26 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Val, Cel and Met XR Low
Description: 500 mg metformin-HCL XR plus 100 mg celecoxib once-a-day in the morning and 160 mg valsartan 6 hours later once-a-day in the afternoon for 26 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Val, Cel and Met XR High
Description: 1000 mg metformin-HCL XR plus 200 mg celecoxib once-a-day in the morning and 320 mg valsartan once-a-day 6 hours later in the afternoon for 26 weeks.
Study: NCT06019780

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood flow restriction trainin
Description: Following exercise will be performed~1. Side lying external rotation~2. Prone horizontal abduction~3. Standing scaption İndividual in the group will be having two session per week, 16 session of exercise training for 8 weeks.50% of arterial occlusion pressure (60 to 80 mmHg) will be applied for total duration of 15mins. Occlusion pressure will be calculated according to formula for each patient \[Pressure=0.4x(systolic BP)+2.7x(shoulder circumference)+62\].4 sets with one set of 30 repetition and three sets of 15 repetition. After each set subject will have 30 seconds of rest with cuff inflated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: Following exercises will be performed without application of pneumatic cuff~1. Side lying external rotation~2. Prone horizontal abduction~3. Standing scaption Conventional treatment will include: Hot pack 5 mins Maitland grade 3 and 4 mobilization: inferior glide (10reps x3sets), posterior glide (10reps x 3sets), anterior glide (10 reps x 3sets) Home plan: wand exercise, pendulum exercise, wall walking exercise (10reps x 2sets each)
Study: NCT05130034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation
Description: Home-based tablet-assisted pulmonary rehabilitation with monitoring technology and telephonic health coach calls using motivational interviewing techniques
Study: NCT06681779

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation
Description: Transcutaneous electrical stimulation will be used to create noxious stimuli for the GCS exam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation
Description: Transcutaneous electrical stimulation will be used to create noxious stimuli for the GCS exam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation
Description: Transcutaneous electrical stimulation will be used to create noxious stimuli for the GCS exam
Study: NCT06081361

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prothionamide
Description: Oral, 600mg qd for weight \<50kg, 600-800mg qd for weight ≥50kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide
Description: Oral, 1500mg qd for weight \<50kg, 1750mg qd for weight ≥50kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Para-Aminosalicylic Acid
Description: 8000mg qd for weight \<50kg, 10000mg qd for weight ≥50kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Description: 750mg qd for weight \<50kg, 1000mg qd for weight ≥50kg
Study: NCT06037382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mood Triggers App
Description: The current intervention will deploy a smartphone application called Mood Triggers. Mood Triggers was designed to provide personalized feedback on individuals' maintenance factors (i.e., triggers) of their anxiety and depressive symptoms based on the theory that such feedback will lead to symptom reduction.
Study: NCT06500286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marciane
Description: Group A caudal block 0.25% bupivacaine was administered at a dose of 0.2 ml/k

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marcaine
Description: Dorsal penil block 0.25% bupivacaine was administered at a dose of 0.2 ml/k
Study: NCT04291521

Intervention type: DRUG
Intervention: Ketamine
Description: Administering ketamine as an induction medication for intubating adult trauma patients within 24 hours of hospital admission.

Intervention type: DRUG
Intervention: Etomidate
Description: Administering etomidate as an induction medication for intubating adult trauma patients within 24 hours of hospital admission.

Intervention type: DRUG
Intervention: Propofol
Description: Administering propofol as an induction medication for intubating adult trauma patients within 24 hours of hospital admission.
Study: NCT05653674

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment approach-based psychoeducation
Description: The psychoeducation based on acceptance and commitment approach reducing psychological distress in nursing students; It has been prepared to increase psychological flexibility, mindfullness and level valuing. A potential approach that has been shown to be effective in reducing psychological distress is one of the third generation cognitive behavioral therapies; acceptance and commitment therapy. Acceptance and commitment-based approaches encourage participants to change their relationship with their thoughts and physical sensations through acceptance, mindfullness, and value-based action mechanisms.
Study: NCT06044727

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive non surgical periodontal therapy
Description: using Magnifying loupes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional subgingival instrumentation
Description: Conventional subgingival instrumentation
Study: NCT05850884

Intervention type: DIAGNOSTIC_TEST
Intervention: stool examination
Description: Each collected sample will be divided into three parts; 1st part will be examined freshly without preservatives by macroscopic and microscopic examination, the 2nd part will be preserved for concentration techniques, staining, and microscopic examination and the 3rd part will be cultivated for Strongyloides stercoralis diagnosis

Intervention type: DIAGNOSTIC_TEST
Intervention: stool examination
Description: Each collected sample will be divided into three parts; 1st part will be examined freshly without preservatives by macroscopic and microscopic examination, the 2nd part will be preserved for concentration techniques, staining, and microscopic examination and the 3rd part will be cultivated for Strongyloides stercoralis diagnosis
Study: NCT06681779

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation
Description: Transcutaneous electrical stimulation will be used to create noxious stimuli for the GCS exam

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC)
Description: Physical pain stimulation, as used in traditional standard care, will be used to score the GCS exam, and the device results will be compared to this SOC exam.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC)
Description: Physical pain stimulation, as used in traditional standard care, will be used to score the GCS exam, and the device results will be compared to this SOC exam.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC)
Description: Physical pain stimulation, as used in traditional standard care, will be used to score the GCS exam, and the device results will be compared to this SOC exam.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC)
Description: Physical pain stimulation, as used in traditional standard care, will be used to score the GCS exam, and the device results will be compared to this SOC exam.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC)
Description: Physical pain stimulation, as used in traditional standard care, will be used to score the GCS exam, and the device results will be compared to this SOC exam.
Study: NCT06002178

Intervention type: DIAGNOSTIC_TEST
Intervention: Neck ultrasound
Description: A neck ultrasound will be performed in order to map superficial arteries and veins of the neck
Study: NCT06681779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC)
Description: Physical pain stimulation, as used in traditional standard care, will be used to score the GCS exam, and the device results will be compared to this SOC exam.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC)
Description: Physical pain stimulation, as used in traditional standard care, will be used to score the GCS exam, and the device results will be compared to this SOC exam.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC)
Description: Physical pain stimulation, as used in traditional standard care, will be used to score the GCS exam, and the device results will be compared to this SOC exam.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC)
Description: Physical pain stimulation, as used in traditional standard care, will be used to score the GCS exam, and the device results will be compared to this SOC exam.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC)
Description: Physical pain stimulation, as used in traditional standard care, will be used to score the GCS exam, and the device results will be compared to this SOC exam.
Study: NCT06115746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iDECIDE
Description: iDECIDE is a 4-session drug education and diversion program that addresses topics such as the neurobiology and addiction, adolescent brain development, industry tactics, motives for using substances, risk and protective factors, identifying triggers, healthy alternatives, core values, and long-term goal setting. These topics are taught via facilitated discussions, videos, worksheets, and handouts. The iDECIDE drug curriculum will be delivered weekly for 4 weeks via videoconference or in-person visits. Each session typically takes 60-75 minutes. For this study, facilitators are members of study staff.
Study: NCT06679959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC30
Description: Injection, for subcutaneous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC30
Description: Injection, for subcutaneous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC30
Description: Injection, for subcutaneous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC30
Description: Injection, for subcutaneous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC30
Description: Injection, for subcutaneous use

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injection, for subcutaneous use

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injection, for subcutaneous use

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injection, for subcutaneous use

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injection, for subcutaneous use

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injection, for subcutaneous use
Study: NCT06680531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-1139 tablets
Description: YZJ-1139 tablets are administered orally single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram oxalate tablets
Description: •oral tablet, QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram oxalate tablets
Description: •oral tablet, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-1139 simulated tablets
Description: oral tablet, QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: YZJ-1139 simulated tablets
Description: oral tablet, QD
Study: NCT04750668

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multisensory Balance Training
Description: Multisensory Balance training includes 30 minutes per day, 5 days a week for 4 weeks, using visual, proprioceptive, and vestibular manipulations. The exercises involved movements of the eye, head, and body to stimulate the vestibular system, postural control exercises in different positions (feet together, tandem stance, and one leg stance), use of a soft surface to reduce the proprioceptive inputs, and exercises with closed eyes to deprive them of visual cues.
Study: NCT06680349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-CD20 antibodies
Description: comparing anti-CD20 (lymphoma protcol, RTX 375 mg/m2 every 4 weeks ) alone Vs. Intensive B-cell depletion therapy (IBCDT) which is based on the combination of RTX (given at the dose of 375 mg/m2 every 4 weeks followed by 2 additional doses after 1 and 2 months), cyclophosphamide (two pulses of 10 mg/kg, corrected according to renal function, on days 4 and 17) and methylprednisolone (three bolus doses of 15 mg/kg) followed by oral prednisone (starting dose 50 mg tapered until complete discontinuation in 4 months).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-CD20 antibodies
Description: comparing anti-CD20 (lymphoma protcol, RTX 375 mg/m2 every 4 weeks ) alone Vs. Intensive B-cell depletion therapy (IBCDT) which is based on the combination of RTX (given at the dose of 375 mg/m2 every 4 weeks followed by 2 additional doses after 1 and 2 months), cyclophosphamide (two pulses of 10 mg/kg, corrected according to renal function, on days 4 and 17) and methylprednisolone (three bolus doses of 15 mg/kg) followed by oral prednisone (starting dose 50 mg tapered until complete discontinuation in 4 months).
Study: NCT06623682

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic cognitive behavioural therapy
Description: Transdiagnostic cognitive behavioural therapy for both depression and anxiety that including modules from (1) Mindfulness-based intervention, (2) Rumination-focused cognitive behavioural therapy, and also including modules for insomnia and from Mindwork (Internet-based cognitive behavioural therapy).
Study: NCT05169281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Disposal Packet
Description: The disposal packet (DisposeRx Inc.) contains a powder that sequesters unused opioids in a polymer gel. The kits reached patients four days following their surgery based on prior data to leverage availability bias, or a tendency to think or act on things that are most present in one's mind, and provided patients with a disposal technique when they were likely to be finished with their opioids. The process of mailing the disposal packet is simple, low cost (\~$1.50/ mailed packet) and scalable.
Study: NCT06680882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular Acupoint Stimulation +prucapride
Description: The study group, comprising 30 individuals, received a combination therapy of non-invasive auricular acupoint stimulation and prucapride

Intervention type: DRUG
Group type: OTHER
Intervention: prucapride
Description: was administered prucapride as a monotherapy
Study: NCT05092971

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shock or startle device
Description: Shock and startle devices were used as aversive stimulus (shock and startle)
Study: NCT06199687

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of Virtual Reality
Description: Use of Virtual Reality after After Thyroid-Parathyroid Surgery